Peptide Libraray

PTP2

General Information

DRACP ID DRACP00100

Peptide Name PTP2

Sequence FAGLAANFLPTIICKISYKC

Sequence Length 20

UniProt ID Not available

PubChem CID Not available

Origin Synthetic

Type Synthetic peptide

Classification

Active ACP Induce apoptosis

Activity Information

Cell Line	Disease	Cancer Classified	Activity	Assay	Testing Time	Literature
A549	Lung adenocarcinoma	Carcinoma	IC50>100 µg/ml	MTT assay	96 h	1
PC-3	Prostate carcinoma	Carcinoma	IC50>100 µg/ml	MTT assay	96 h	1
Hep 3B	Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma	Carcinoma	IC50>100 µg/ml	MTT assay	96 h	1
MCF-7	Invasive breast carcinoma of no special type	Carcinoma	IC50>100 µg/ml	MTT assay	96 h	1

Hemolytic Activity Human RBCs: less than 6% hemolysis at 100 μg/ml

Normal (non-cancerous) Cytotoxicity HEK293: IC50>100 µg/ml

Target Not available

Affinity Not available

Mechanism Not available

Nature Anticancer; Antimicrobial

Structure Information

PDB ID Not available

Predicted Structure DRACP00100

Helicity Not available

Linear/Cyclic Cyclic

Disulfide/Other Bond Cys14<--->Cys20

N-terminal Modification Free

C-terminal Modification Amidation

Other Modification None

Chiral L

Physicochemical Information

Formula C102H161N23O25S2

Absent amino acids DEHMQRVW

Common amino acids AI

Mass 251276

Pl 8.79

Basic residues 2

Acidic residues 0

Hydrophobic residues 10

Net charge 2

Boman Index 1564

Hydrophobicity 105

Aliphatic Index 112.5

Half Life
Mammalian: 5.5 hour
Yeast: 3 min
E.coli: 2 min

Extinction Coefficient cystines 1615

Absorbance 280nm 85

Polar residues 7

Amino acid distribution

Literature Information

Literature 1

Pubmed ID 14499271

Title In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines

Doi 10.1016/s0196-9781(03)00194-3

Year 2003

Patent

Patent ID Not available

Patent Title Not available

Other Iinformation Not available

Other Published ID Not available